Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Plus Lenalidomide in MALT Lymphoma
NCT01611259Phase 2Completed
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- May 2012
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Primary endpoint: Objective Responses at 40 weeks. Started May 2012; status: completed.
02
Drugs
lenalidomide
03
Conditions
extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
Beyond the preview
Go deeper on NCT01611259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01611259.